Jacobio Pharmaceuticals Group Co., Ltd.
1167.HK · HKSE
Market closed4.65-0.570000 (-10.92%)
Key statistics
Previous close5.22
Open5.17
Day high5.19
Day low4.61
52-week high11.80
52-week low3.98
Market cap3.64B
Volume4.19M
Average volume3.08M
P/E ratio-44.69
Forward P/E—
EPS-0.10
Dividend yield0.00%
Market context
Why it moved
In the absence of directly relevant news for 1167.HK, the sharp decline appears to be driven by broad selling pressure and negative market sentiment in the Hong Kong market, likely compounded by sector-specific concerns weighing heavily on the stock.
What is happening
Recent company-specific developments and publisher coverage.
Caixin Global · March 12, 2026$100 Million AstraZeneca Deal Puts Chinese Biotech Jacobio on Path to ProfitChina Daily · December 25, 2025Jacobio, AstraZeneca ink cancer drug dealBloomberg.com · December 22, 2025Watch Jacobio Strikes New Cancer Drug Deal with AstraZenecaClinical Trials Arena · December 1, 2025Jacobio’s NSCLC combo touts 71% ORR in Phase I/IIa trial Mt Newswire · June 8, 2026Jacobio Pharmaceuticals Launches HK$100 Million Share Buyback Mt Newswire · May 19, 2026Jacobio Pharmaceuticals Says Cash Runway Extends at Least Four Years Mt Newswire · March 11, 2026Jacobio Pharmaceuticals' 2025 Loss Narrows Mt Newswire · December 22, 2025Jacobio Pharmaceuticals Sells JAB-23E73 License to AstraZeneca Mt Newswire · December 3, 2025Jacobio Pharmaceuticals Unit Receives Upfront Payment From Oceanpine Capital; Shares Lose 3% Mt Newswire · November 13, 2025Jacobio Pharmaceuticals Appoints Co-CEO Mt Newswire · October 16, 2025Jacobio Pharmaceuticals Unit to Sell 80% Stake in Jacoray to Oceanpine Capital